CA3043610A1 - Crystalline forms of a magl inhibitor - Google Patents
Crystalline forms of a magl inhibitor Download PDFInfo
- Publication number
- CA3043610A1 CA3043610A1 CA3043610A CA3043610A CA3043610A1 CA 3043610 A1 CA3043610 A1 CA 3043610A1 CA 3043610 A CA3043610 A CA 3043610A CA 3043610 A CA3043610 A CA 3043610A CA 3043610 A1 CA3043610 A1 CA 3043610A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- crystalline form
- theta
- crystalline
- hexafluoropropan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423126P | 2016-11-16 | 2016-11-16 | |
| US62/423,126 | 2016-11-16 | ||
| PCT/US2017/061875 WO2018093953A1 (en) | 2016-11-16 | 2017-11-15 | Crystalline forms of a magl inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3043610A1 true CA3043610A1 (en) | 2018-05-24 |
Family
ID=62145805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3043610A Pending CA3043610A1 (en) | 2016-11-16 | 2017-11-15 | Crystalline forms of a magl inhibitor |
Country Status (38)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9487495B2 (en) | 2012-01-06 | 2016-11-08 | The Scripts Research Institute | Carbamate compounds and of making and using same |
| SG10202012002TA (en) | 2015-05-11 | 2021-01-28 | Lundbeck La Jolla Research Center Inc | Methods of treating inflammation or neuropathic pain |
| JP7042804B2 (ja) | 2016-09-19 | 2022-03-28 | ルンドベック ラ ホーヤ リサーチ センター，インク． | ピペラジンカルバメート、及びその製造と使用の方法 |
| KR20190085046A (ko) | 2016-11-16 | 2019-07-17 | 어바이드 테라퓨틱스, 인크. | 약학 제제 |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| DK3541807T3 (da) | 2016-11-16 | 2021-12-06 | H Lundbeck As | Krystallinsk form af en magl-inhibitor |
| EA201992409A1 (ru) | 2017-05-23 | 2020-03-23 | Лундбекк Ла-Хойя Рисерч Сентер, Инк. | Ингибиторы magl на основе пиразола |
| US10927105B1 (en) | 2017-05-23 | 2021-02-23 | Lundbeck La Jolla Research Center, Inc. | Pyrazole MAGL inhibitors |
| JP7257387B2 (ja) | 2017-08-29 | 2023-04-13 | ハー・ルンドベック・アクチエゼルスカベット | スピロ環化合物並びにその作製及び使用方法 |
| KR20210010475A (ko) * | 2018-05-15 | 2021-01-27 | 룬드벡 라 졸라 리서치 센터 인코포레이티드 | Magl 저해제 |
| AU2019304198A1 (en) * | 2018-07-19 | 2021-02-04 | Pfizer Inc. | Heterocyclic spiro compounds as MAGL inhibitors |
| PE20211089A1 (es) | 2018-08-13 | 2021-06-14 | Hoffmann La Roche | Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa |
| WO2020104494A1 (en) | 2018-11-22 | 2020-05-28 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
| MA54827A (fr) * | 2019-01-25 | 2022-05-04 | H Lundbeck As | Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de magl |
| KR20220101095A (ko) * | 2019-11-15 | 2022-07-19 | 하. 룬드벡 아크티에셀스카브 | Magl 억제제의 결정형 |
| IL297470A (en) | 2020-04-21 | 2022-12-01 | H Lundbeck As | Synthesis of a monoacylglycerol lipase inhibitor |
| WO2023092079A1 (en) * | 2021-11-19 | 2023-05-25 | Bryant Cynthia W | Use of cannabinoid compounds to treat gastrointestinal disorders |
| CA3242372A1 (en) | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| KR20250005229A (ko) | 2022-05-04 | 2025-01-09 | 하. 룬드벡 아크티에셀스카브 | 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태 |
| CN117665187B (zh) * | 2023-11-23 | 2024-08-16 | 宁波大红鹰药业股份有限公司 | 一种舒林酸中间体杂质的测定方法 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| WO1992018106A1 (fr) | 1991-04-16 | 1992-10-29 | Nippon Shinyaku Co., Ltd. | Procede de production d'une dispersion solide |
| HU227530B1 (en) | 1991-11-22 | 2011-07-28 | Warner Chilcott Company | Delayed-release compositions containing risedronate and process for their production |
| US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| JP2616252B2 (ja) | 1992-10-16 | 1997-06-04 | 日本新薬株式会社 | ワックスマトリックスの製法 |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| JPH11505258A (ja) | 1995-05-17 | 1999-05-18 | セダーシナイ メディカル センター | 小腸における消化および吸収を改善させる脂肪酸を含む組成物 |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| HUP0302455A3 (en) | 2000-12-18 | 2005-05-30 | Novartis Ag | Combination pharmaceutical compositions containing amplodipine and benazepril and their use |
| US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| CA2476936A1 (en) | 2002-02-20 | 2003-08-28 | Chih-Hung Lee | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor |
| US7074805B2 (en) | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| KR20070094666A (ko) | 2005-02-25 | 2007-09-20 | 에프. 호프만-라 로슈 아게 | 약제 물질 분산성이 향상된 정제 |
| US7858609B2 (en) | 2005-11-28 | 2010-12-28 | Marinus Pharmaceuticals | Solid ganaxolone formulations and methods for the making and use thereof |
| EP1938804A1 (en) | 2006-12-22 | 2008-07-02 | Novartis AG | Pharmaceutical formulation comprising neurokinin antagonist |
| FR2938341A1 (fr) | 2008-11-13 | 2010-05-14 | Galderma Res & Dev | Modulateurs de la monoglyceride lipase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee |
| WO2010063802A1 (en) | 2008-12-05 | 2010-06-10 | Novartis Ag | 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists |
| CN101530399B (zh) | 2009-04-15 | 2011-01-26 | 江苏中兴药业有限公司 | 一种水飞蓟宾固体自乳化片 |
| US9487495B2 (en) | 2012-01-06 | 2016-11-08 | The Scripts Research Institute | Carbamate compounds and of making and using same |
| EP2828253A1 (en) | 2012-03-19 | 2015-01-28 | Abide Therapeutics, Inc. | Carbamate compounds and of making and using same |
| EP2844247A4 (en) | 2012-04-20 | 2015-11-25 | Anderson Gaweco | ROR MODULATORS AND ITS USES |
| LT3470063T (lt) | 2012-11-02 | 2025-02-10 | Vertex Pharmaceuticals Incorporated | Farmacinės kompozicijos, skirtos cftr nulemtų ligų gydymui |
| TW201446286A (zh) | 2013-01-31 | 2014-12-16 | Gilead Pharmasset Llc | 抗病毒化合物之固態分散調製劑 |
| US9551036B2 (en) | 2013-02-25 | 2017-01-24 | Whitehead Institute For Biomedical Research | Metabolic gene mesenchymal signatures and uses thereof |
| CA2917050A1 (en) | 2013-07-03 | 2015-01-08 | Todd K. Jones | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof |
| US20150064252A1 (en) | 2013-08-27 | 2015-03-05 | Gilead Pharmasset Llc | Solid dispersion formulation of an antiviral compound |
| CN103893258B (zh) | 2013-12-05 | 2017-09-29 | 人福医药集团股份公司 | 含有广金钱草总黄酮的口服固体制剂及其应用 |
| EP3134092B1 (en) * | 2014-04-21 | 2020-06-24 | Merck Sharp & Dohme Corp. | Pharmaceutical salts of an orexin receptor antagonist |
| WO2015179559A2 (en) * | 2014-05-21 | 2015-11-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| ES2878041T3 (es) | 2015-03-18 | 2021-11-18 | H Lundbeck As | Carbamatos de piperazina y métodos para prepararlos y usarlos |
| SG10202012002TA (en) | 2015-05-11 | 2021-01-28 | Lundbeck La Jolla Research Center Inc | Methods of treating inflammation or neuropathic pain |
| WO2017143283A1 (en) * | 2016-02-19 | 2017-08-24 | Abide Therapeutics, Inc. | Radiolabeled monoacylglycerol lipase occupancy probe |
| DK3541807T3 (da) | 2016-11-16 | 2021-12-06 | H Lundbeck As | Krystallinsk form af en magl-inhibitor |
| JOP20190105A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| KR20190085046A (ko) | 2016-11-16 | 2019-07-17 | 어바이드 테라퓨틱스, 인크. | 약학 제제 |
| JOP20190106A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
-
2017
- 2017-11-15 DK DK17872429.0T patent/DK3541807T3/da active
- 2017-11-15 JO JOP/2019/0109A patent/JOP20190109B1/ar active
- 2017-11-15 MA MA46866A patent/MA46866B1/fr unknown
- 2017-11-15 CN CN202210681321.7A patent/CN115093382A/zh active Pending
- 2017-11-15 ES ES21199077T patent/ES2966939T3/es active Active
- 2017-11-15 PT PT178724290T patent/PT3541807T/pt unknown
- 2017-11-15 SM SM20210675T patent/SMT202100675T1/it unknown
- 2017-11-15 WO PCT/US2017/061875 patent/WO2018093953A1/en not_active Ceased
- 2017-11-15 RS RS20231263A patent/RS65016B1/sr unknown
- 2017-11-15 EA EA201991086A patent/EA201991086A1/ru unknown
- 2017-11-15 PE PE2019001013A patent/PE20191239A1/es unknown
- 2017-11-15 CA CA3043610A patent/CA3043610A1/en active Pending
- 2017-11-15 JP JP2019523672A patent/JP7042548B2/ja not_active Expired - Fee Related
- 2017-11-15 KR KR1020197017161A patent/KR102508739B1/ko active Active
- 2017-11-15 GE GEAP201715091A patent/GEP20237559B/en unknown
- 2017-11-15 TN TNP/2019/000151A patent/TN2019000151A1/en unknown
- 2017-11-15 EP EP17872429.0A patent/EP3541807B1/en active Active
- 2017-11-15 EP EP21199077.5A patent/EP3964503B1/en active Active
- 2017-11-15 UA UAA201905624A patent/UA124585C2/uk unknown
- 2017-11-15 GE GEAP202315091A patent/GEAP202315091A/en unknown
- 2017-11-15 HU HUE17872429A patent/HUE056973T2/hu unknown
- 2017-11-15 AU AU2017361257A patent/AU2017361257B2/en not_active Ceased
- 2017-11-15 PL PL17872429T patent/PL3541807T3/pl unknown
- 2017-11-15 CN CN201780083644.3A patent/CN110291083B/zh not_active Expired - Fee Related
- 2017-11-15 MX MX2019005767A patent/MX389459B/es unknown
- 2017-11-15 LT LTEPPCT/US2017/061875T patent/LT3541807T/lt unknown
- 2017-11-15 HR HRP20231697TT patent/HRP20231697T1/hr unknown
- 2017-11-15 RS RS20211501A patent/RS62665B1/sr unknown
- 2017-11-15 SI SI201730987T patent/SI3541807T1/sl unknown
- 2017-11-15 MA MA58133A patent/MA58133B1/fr unknown
- 2017-11-15 MY MYPI2019002687A patent/MY199386A/en unknown
- 2017-11-15 US US16/349,142 patent/US11142517B2/en active Active
- 2017-11-15 PL PL21199077.5T patent/PL3964503T3/pl unknown
- 2017-11-15 SM SM20230494T patent/SMT202300494T1/it unknown
- 2017-11-15 HU HUE21199077A patent/HUE064559T2/hu unknown
- 2017-11-15 CR CR20190242A patent/CR20190242A/es unknown
- 2017-11-15 BR BR112019010003A patent/BR112019010003A2/pt not_active Application Discontinuation
- 2017-11-15 HR HRP20211863TT patent/HRP20211863T1/hr unknown
- 2017-11-15 ES ES17872429T patent/ES2900016T3/es active Active
-
2019
- 2019-05-12 IL IL266548A patent/IL266548A/en unknown
- 2019-05-14 PH PH12019501068A patent/PH12019501068A1/en unknown
- 2019-05-16 NI NI201900053A patent/NI201900053A/es unknown
- 2019-05-16 EC ECSENADI201935171A patent/ECSP19035171A/es unknown
- 2019-05-16 CO CONC2019/0005045A patent/CO2019005045A2/es unknown
- 2019-05-16 MX MX2022000249A patent/MX2022000249A/es unknown
- 2019-05-16 CL CL2019001340A patent/CL2019001340A1/es unknown
- 2019-05-16 DO DO2019000120A patent/DOP2019000120A/es unknown
- 2019-05-17 ZA ZA2019/03093A patent/ZA201903093B/en unknown
-
2021
- 2021-09-08 US US17/469,535 patent/US11993588B2/en active Active
- 2021-12-13 CY CY20211101092T patent/CY1124870T1/el unknown
-
2022
- 2022-03-08 JP JP2022035398A patent/JP7350117B2/ja active Active
-
2024
- 2024-01-29 CY CY20241100067T patent/CY1126586T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11993588B2 (en) | Crystalline forms of a MAGL inhibitor | |
| JP2025026857A (ja) | 痛風または高尿酸血症を処置または予防するための化合物の結晶形態 | |
| RS66922B1 (sr) | Kristalni oblici metil (s)‑2‑((2‑(2,6-difluoro‑4‑(metilkarbamoil)fenil)‑7-metilimidazo[1,2-a]piridin‑3-il)metil)morfolin‑4-karboksilata modulatora p2x3 | |
| US9956201B2 (en) | Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms | |
| HK40069310A (en) | A crystalline form of a magl inhibitor | |
| HK40069310B (en) | A crystalline form of a magl inhibitor | |
| RU2799564C2 (ru) | Кристаллические формы ингибитора magl | |
| HK40009165A (en) | A crystalline form of a magl inhibitor | |
| HK40009165B (en) | A crystalline form of a magl inhibitor | |
| WO2024011142A1 (en) | Crystalline forms of an s1p receptor modulator | |
| AU2018325267B2 (en) | Crystalline forms of compounds for preventing or treating sensory hair cell death | |
| EA041551B1 (ru) | Кристаллические формы ингибитора magl | |
| NZ753241B2 (en) | Crystalline forms of a magl inhibitor | |
| WO2026085383A1 (en) | Crystalline forms of an nlrp3 modulator | |
| EP4551576A1 (en) | Crystalline forms of a tyk2 inhibitor | |
| WO2017073738A1 (ja) | フェキソフェナジンを有効成分とする錠剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220921 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251111 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260106 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260107 |